Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways
Background Doxorubicin is an effective, potent and commonly used anthracycline-related anticancer drug; however, cardiotoxicity compromises its therapeutic potential. Apremilast, a novel phosphodiesterase type 4-inhibitor, reported to have anti-inflammatory effects and modulating many inflammatory mediators. Methods The present study investigated the influence of apremilast against doxorubicin-induced cardiotoxicity in male Wistar rats. A total, 24 animals were divided into four groups of six animal each. Group 1, served as control and received normal saline. Group 2 animals, received doxorubicin (20 mg $ kg^{−1} $, ip). Group 3 and 4, treatment group, received doxorubicin (20 mg $ kg^{−1} $, ip) with the same schedule as group-2, plus apremilast (10 and 20 mg $ kg^{−1} $ $ day^{−1} $, po) respectively. Oxidative stress, caspase-3 enzyme activity, gene expression and protein expression were tested. Results The results of the present study demonstrated that administration of apremilast reversed doxorubicin-induced cardiotoxicity. Conclusion These findings suggested that apremilast can attenuate doxorubicin-induced cardiotoxicity via inhibition of oxidative stress mediated activation of nuclear factor-kappa B signaling pathways..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
---|---|
Enthalten in: |
Pharmacological reports - 70(2018), 5 vom: 29. März, Seite 993-1000 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Imam, Faisal [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Apremilast |
---|
Anmerkungen: |
© Maj Institute of Pharmacology Polish Academy of Sciences 2018 |
---|
doi: |
10.1016/j.pharep.2018.03.009 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR038902079 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR038902079 | ||
003 | DE-627 | ||
005 | 20230816064700.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.pharep.2018.03.009 |2 doi | |
035 | |a (DE-627)SPR038902079 | ||
035 | |a (SPR)j.pharep.2018.03.009-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Imam, Faisal |e verfasserin |4 aut | |
245 | 1 | 0 | |a Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Maj Institute of Pharmacology Polish Academy of Sciences 2018 | ||
520 | |a Background Doxorubicin is an effective, potent and commonly used anthracycline-related anticancer drug; however, cardiotoxicity compromises its therapeutic potential. Apremilast, a novel phosphodiesterase type 4-inhibitor, reported to have anti-inflammatory effects and modulating many inflammatory mediators. Methods The present study investigated the influence of apremilast against doxorubicin-induced cardiotoxicity in male Wistar rats. A total, 24 animals were divided into four groups of six animal each. Group 1, served as control and received normal saline. Group 2 animals, received doxorubicin (20 mg $ kg^{−1} $, ip). Group 3 and 4, treatment group, received doxorubicin (20 mg $ kg^{−1} $, ip) with the same schedule as group-2, plus apremilast (10 and 20 mg $ kg^{−1} $ $ day^{−1} $, po) respectively. Oxidative stress, caspase-3 enzyme activity, gene expression and protein expression were tested. Results The results of the present study demonstrated that administration of apremilast reversed doxorubicin-induced cardiotoxicity. Conclusion These findings suggested that apremilast can attenuate doxorubicin-induced cardiotoxicity via inhibition of oxidative stress mediated activation of nuclear factor-kappa B signaling pathways. | ||
650 | 4 | |a Apremilast |7 (dpeaa)DE-He213 | |
650 | 4 | |a Inflammation |7 (dpeaa)DE-He213 | |
650 | 4 | |a Cardiotoxicity |7 (dpeaa)DE-He213 | |
650 | 4 | |a Doxorubicin |7 (dpeaa)DE-He213 | |
650 | 4 | |a Nuclear factor-kappa B |7 (dpeaa)DE-He213 | |
700 | 1 | |a Al-Harbi, Naif O. |4 aut | |
700 | 1 | |a Al-Harbi, Mohammad Matar |4 aut | |
700 | 1 | |a Ansari, Mushtaq Ahmad |4 aut | |
700 | 1 | |a Al-Asmari, Abdullah F. |4 aut | |
700 | 1 | |a Ansari, Mohd Nazam |4 aut | |
700 | 1 | |a Al-Anazi, Wael A. |4 aut | |
700 | 1 | |a Bahashwan, Saleh |4 aut | |
700 | 1 | |a Almutairi, Mashal M. |4 aut | |
700 | 1 | |a Alshammari, Musaad |4 aut | |
700 | 1 | |a Khan, Mohammad Rashid |4 aut | |
700 | 1 | |a Alsaad, Abdulaziz Mohammed |4 aut | |
700 | 1 | |a Alotaibi, Moureq Rashed |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacological reports |d Heidelberg : Springer Nature, 1998 |g 70(2018), 5 vom: 29. März, Seite 993-1000 |w (DE-627)SPR038875861 |w (DE-600)2129019-2 |x 2299-5684 |7 nnns |
773 | 1 | 8 | |g volume:70 |g year:2018 |g number:5 |g day:29 |g month:03 |g pages:993-1000 |
856 | 4 | 0 | |u https://dx.doi.org/10.1016/j.pharep.2018.03.009 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 70 |j 2018 |e 5 |b 29 |c 03 |h 993-1000 |